Brief: Ipsen SA Says Late-Breaking Analysis Demonstrates Characteristics Associated With Long-Term Overall Survival With Onivyde Regimen In Metastatic Pancreatic Adenocarcinoma
31/05/2025 13:13
May 31 (Reuters) - Ipsen SA IPN.PA: IPSEN SA: LATE-BREAKING ANALYSIS DEMONSTRATES CHARACTERISTICS ASSOCIATED WITH LONG-TERM OVERALL SURVIVAL WITH ONIVYDE REGIMEN IN METASTATIC PANCREATIC ADENOCARCINOMA IPSEN SA: DOSE REDUCTIONS AND/OR TREATMENT DELAYS FOR MANAGEMENT OF ADVERSE EVENTS ENABLED PATIENTS TO STAY ON TREATMENT LONGER IPSEN SA: ANALYSIS OF NAPOLI 3 STUDY DETERMINED CHARACTERISTICS ASSOCIATED WITH LONG-TERM SURVIVAL Source text: ID:nGNE7t3VM6 Further company coverage: IPN.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio